Short-interval second ejaculation improves sperm quality, blastocyst formation in oligoasthenozoospermic males in ICSI cycles: a time-lapse sibling oocytes study.
abstinence period
embryo development
sibling oocyte
sperm quality
time lapse
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
06
2023
accepted:
21
08
2023
medline:
26
9
2023
pubmed:
25
9
2023
entrez:
25
9
2023
Statut:
epublish
Résumé
Does short-interval second ejaculation improve sperm quality, embryo development and clinical outcomes for oligoasthenozoospermia males received intracytoplasmic sperm injection (ICSI) treatment? All enrolled male patients underwent short-interval secondary ejaculation on the day of oocyte retrieval, and 786 sibling MII oocytes from 67 cycles were equally divided into two groups based on whether the injected spermatozoons originated from the first or second ejaculation. Semen parameters, embryo development efficiency, morphokinetic parameters and clinical outcomes were compared between the two groups to assess the efficiency and clinical value of short-interval second ejaculation in ICSI cycles. Short-interval second ejaculation significantly improved sperm motility, normal morphological rate, and sperm DNA integrity both before and after sperm swim-up. The high-quality blastocyst rate (24.79% versus 14.67%), available blastocyst rate (57.56% versus 48.44%), and oocyte utilization rate (52.93% versus 45.29%) were significantly higher in the second ejaculation group ( Short-interval second ejaculation significantly improves sperm quality in oligoasthenozoospermic males, and is beneficial for blastocyst formation efficiency in ICSI cycles. This study suggested a non-invasive and simple but effective strategy for improving ICSI treatment outcomes.
Sections du résumé
Background
Does short-interval second ejaculation improve sperm quality, embryo development and clinical outcomes for oligoasthenozoospermia males received intracytoplasmic sperm injection (ICSI) treatment?
Methods
All enrolled male patients underwent short-interval secondary ejaculation on the day of oocyte retrieval, and 786 sibling MII oocytes from 67 cycles were equally divided into two groups based on whether the injected spermatozoons originated from the first or second ejaculation. Semen parameters, embryo development efficiency, morphokinetic parameters and clinical outcomes were compared between the two groups to assess the efficiency and clinical value of short-interval second ejaculation in ICSI cycles.
Results
Short-interval second ejaculation significantly improved sperm motility, normal morphological rate, and sperm DNA integrity both before and after sperm swim-up. The high-quality blastocyst rate (24.79% versus 14.67%), available blastocyst rate (57.56% versus 48.44%), and oocyte utilization rate (52.93% versus 45.29%) were significantly higher in the second ejaculation group (
Conclusions
Short-interval second ejaculation significantly improves sperm quality in oligoasthenozoospermic males, and is beneficial for blastocyst formation efficiency in ICSI cycles. This study suggested a non-invasive and simple but effective strategy for improving ICSI treatment outcomes.
Identifiants
pubmed: 37745695
doi: 10.3389/fendo.2023.1250663
pmc: PMC10512860
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1250663Informations de copyright
Copyright © 2023 Li, Wang, Li, Huang, Liu, Zhang, Qin, Mao, Li, Chen, Wei, Shi and Xue.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Fertil Steril. 2014 Sep;102(3):705-10
pubmed: 24993799
Andrologia. 2018 Feb 20;:
pubmed: 29460293
Clin Exp Reprod Med. 2022 Mar;49(1):49-56
pubmed: 35255658
J Assist Reprod Genet. 2019 Aug;36(8):1591-1597
pubmed: 31325068
Int Braz J Urol. 2022 Jan-Feb;48(1):131-156
pubmed: 34472769
Front Endocrinol (Lausanne). 2022 Jan 04;12:802632
pubmed: 35058886
Hum Reprod Update. 2023 Mar 1;29(2):157-176
pubmed: 36377604
Cell Mol Life Sci. 2017 Jun;74(11):1957-1967
pubmed: 28050628
Fertil Steril. 2017 Dec;108(6):988-992
pubmed: 29100624
J Clin Med. 2021 Jul 21;10(15):
pubmed: 34361997
J Assist Reprod Genet. 2015 Dec;32(12):1721-9
pubmed: 26431955
Biol Res. 2022 Dec 26;55(1):41
pubmed: 36572948
Fertil Steril. 2011 Nov;96(5):1083-6
pubmed: 21924714
Mol Reprod Dev. 2020 Apr;87(4):493-502
pubmed: 32064722
Urology. 2017 Oct;108:90-95
pubmed: 28712886
Andrology. 2021 Jul;9(4):1185-1191
pubmed: 33861504
Andrologia. 2019 Jul;51(6):e13263
pubmed: 30838696
Int J Mol Sci. 2023 Feb 09;24(4):
pubmed: 36834909
J Assist Reprod Genet. 2015 Jul;32(7):1049-55
pubmed: 26081127
Mol Cell Proteomics. 2019 Mar 15;18(Suppl 1):S109-S117
pubmed: 30126978
Antioxidants (Basel). 2023 Mar 20;12(3):
pubmed: 36979001
Front Pediatr. 2017 Jun 09;5:135
pubmed: 28649564
J Clin Med. 2021 Mar 02;10(5):
pubmed: 33801210
Fertil Steril. 2018 Feb;109(2):276-283.e3
pubmed: 29331237
Eur Urol. 2021 Nov;80(5):603-620
pubmed: 34511305
Hum Reprod. 2011 Jun;26(6):1270-83
pubmed: 21502182
Andrology. 2020 May;8(3):594-601
pubmed: 31755657
Hum Reprod. 2014 Dec;29(12):2650-60
pubmed: 25344070
Lancet. 2021 Jan 23;397(10271):319-333
pubmed: 33308486
Cell. 2021 May 27;184(11):2860-2877.e22
pubmed: 33964210
Fertil Steril. 2018 Apr;109(4):665-674
pubmed: 29452698
Clin Chem. 2019 Jan;65(1):161-169
pubmed: 30602480
Zygote. 2022 Feb;30(1):72-79
pubmed: 34034847
Syst Biol Reprod Med. 2013 Oct;59(5):256-60
pubmed: 23651301
Fertil Steril. 2000 Jun;73(6):1155-8
pubmed: 10856474
Hum Reprod. 2017 Jul 1;32(7):1364-1372
pubmed: 28531319
Bioessays. 1994 Apr;16(4):259-67
pubmed: 8031303
Front Endocrinol (Lausanne). 2021 Jun 16;12:694325
pubmed: 34220719